IMCC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IM Cannabis Corp (IMCC) is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock is trading pre-market at 0.271, down 4.38%, and the technical setup remains weak with bearish moving averages and a price below the key pivot level. While momentum is slightly improving on MACD, the overall trend is still bearish. The latest quarter showed revenue growth, but profitability remains deeply negative and gross margin deteriorated sharply. With no recent news, no bullish proprietary signal, no meaningful insider or hedge fund support, and no analyst upgrade momentum, the stock lacks a strong long-term buy case at the moment.
Technical picture is weak. MACD histogram is positive and expanding, which suggests some short-term momentum improvement. However, RSI_6 at 36.05 is still neutral and not oversold enough to signal a strong bounce. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a broader downtrend. Current pre-market price of 0.271 is below the pivot at 0.367 and closer to support at 0.245, with deeper support at 0.17. The pattern-based forecast is also negative over the next week and month, suggesting continued downside pressure.
["Revenue in 2025/Q4 increased 17.62% YoY to 15.684 million.", "MACD histogram is above zero and expanding, showing some improving short-term momentum.", "Price is approaching support levels that could attract speculative interest."]
["Pre-market price is down 4.38%, showing immediate weakness.", "Bearish moving average structure confirms the broader trend is still down.", "Net income remains negative at -7.634 million in 2025/Q4.", "EPS remains negative at -1.33.", "Gross margin dropped sharply to 0.52, indicating weaker profitability.", "No news in the recent week, so there are no event-driven bullish catalysts.", "No recent congress trading data available.", "No signal on given stock today for AI Stock Picker or SwingMax.", "Hedge funds are neutral and insiders are neutral, showing no strong conviction buying.", "Stock trend estimates are negative for the next week and month."]
In 2025/Q4, IM Cannabis reported revenue of 15.684 million, up 17.62% year over year, which is a positive growth trend. However, financial quality remains weak because net income was -7.634 million and EPS was -1.33, both still negative despite improving year over year. Gross margin fell sharply to 0.52, suggesting profitability pressure remains significant. Overall, top-line growth is improving, but the latest quarter still does not show a convincing path to durable profitability.
No analyst rating or price target change data was provided, so there is no visible Wall Street pros and cons shift to report. Based on the available information, the Wall Street view appears neutral-to-cautious: some revenue growth is visible, but ongoing losses, weaker margins, bearish technicals, and lack of positive catalyst flow outweigh the upside case.
